- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen Launches Online Healthy Minds Video Series
Promotes Knowledge of Brain Disorders and Encourages Anti-Stigma Efforts
IMBRUVICA® (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p
Approval based on Phase 3 RESONATE data with statistically significant improvements in progression-free and overall survival
Phase 2 COSMOS Study Results Published in The Lancet Demonstrate Efficacy and Safety of Janssen’s Once-Daily Simeprevir in All Oral 12-Week Combination with Sofosbuvir for Genotype 1 Chronic Hepatitis C
Study evaluated interferon-free combination in treatment-naïve and prior null-responder patients with all stages of liver fibrosis, including cirrhosis
Janssen Pharmaceuticals Seeks Expanded Label for Once-Monthly INVEGA® SUSTENNA® (paliperidone palmitate) to Show Delayed Time to Relapse Compared to Daily Oral Schizophrenia Therapies
Submission based on first head-to-head study vs. oral treatments in real world context
Johnson & Johnson Innovation Catalyzes New and Exciting Science and Technology in Pharmaceutical, Medical Device, Diagnostic and Consumer Healthcare Spaces
Deals span new approaches for cancer, diabetes, autoimmune disease and Alzheimer’s, exciting technologies such as 3-D printing for trauma use, sedation monitoring, cardiac remodeling, probiotics for skin infections
New Long-Term Data Show INVOKANA® (canagliflozin) Lowers Blood Glucose in Older Patients with Type 2 Diabetes Inadequately Controlled on Other Therapies
Phase 3 Study Results Also Demonstrate INVOKANA® Reduces Secondary Endpoints of Body Weight and Systolic Blood Pressure